Diabetes: Page 7
-
Courtesy of Abbott Laboratories
Abbott sees ‘signs of stability’ for 2023 as hospital staffing, supply chain improves
While the company continues to grapple with supply shortages and procedure restrictions, it sold more COVID-19 tests than expected in the fourth quarter.
By Elise Reuter • Jan. 25, 2023 -
Courtesy of Insulet Corp.
Insulet reports personal-data leak of 29,000 insulin pump customers
In a recall communication to users, Insulet shared information with its website performance and marketing partners through cookies and other trackers embedded in its website.
By Nick Paul Taylor • Jan. 24, 2023 -
Volodymyr Bushmelov via Getty Images
Deep Dive // Medtech trends in 2023Diabetes outlook: What Dexcom, Medtronic and other leaders are watching in 2023
From new product launches to regulatory changes that could expand CGM coverage, company executives and analysts share their predictions.
By Elise Reuter • Jan. 20, 2023 -
Permission granted by Dexcom
Q&ADexcom CEO discusses 2023 plans, expanding to more patients with Type 2 diabetes
MedTech Dive caught up with Kevin Sayer for a conversation about forthcoming product launches and long-term plans to expand CGMs to a broader group of patients.
By Elise Reuter • Updated Jan. 20, 2023 -
Permission granted by Abbott Laboratories
How Abbott plans to make its Freestyle Libre a $10B product
CEO Robert Ford discussed plans to grow the market for Abbott’s continuous glucose monitors, and its broader diabetes strategy.
By Elise Reuter • Jan. 10, 2023 -
Courtesy of Beta Bionics
Beta Bionics hires Harvard diabetes expert as CMO ahead of artificial pancreas launch
Steven Russell has joined the company as chief medical officer, completing a new leadership team that began taking shape with the appointment of Sean Saint as CEO last year.
By Nick Paul Taylor • Jan. 10, 2023 -
Courtesy of Dexcom
Dexcom forecasts 2023 revenue to rise as much as 20% on G7 launch
Sales are expected to reach $3.35 billion to $3.49 billion for the full year.
By Elise Reuter • Jan. 9, 2023 -
Courtesy of Medtronic
‘Mea culpa’: What Goldman Sachs analysts got wrong about Medtronic in 2022
Medtronic has struggled to deliver on key projects in recent years, leading to a decline in its stock performance.
By Nick Paul Taylor • Jan. 4, 2023 -
Pixelseffect via Getty Images
As diabetes technology advances, blood glucose control declines: study
Mexican-American and non-Hispanic Black adults saw the greatest drop as the proportion of patients with glycemic control fell from 29.2% between 1988 and 1994 to 27.5% between 2013 and 2020.
By Nick Paul Taylor • Dec. 21, 2022 -
Samara Heisz via Getty Images
Novo Nordisk expands Amalgam Rx insulin app pact, plots integration with other devices
Supported by Novo Nordisk, Amalgam Rx will incorporate and integrate with connected insulin delivery devices, continuous glucose monitors and electronic health records.
By Nick Paul Taylor • Dec. 20, 2022 -
Courtesy of Dexcom
Dexcom’s Jake Leach discusses preparations for G7 launch next year
The diabetes tech company is in conversations with payers and is opening a new manufacturing plant ahead of the planned launch of its newest CGM, the COO said.
By Elise Reuter • Dec. 15, 2022 -
Courtesy of Tandem Diabetes
Tandem agrees to buy AMF, challenging Insulet for insulin pump patch market
The deal will give Tandem control of Sigi, a reusable, rechargeable patch pump that is designed to be smaller and lighter than existing devices.
By Nick Paul Taylor • Dec. 14, 2022 -
Courtesy of Ypsomed
Ypsomed seeks new partner for US insulin pump launch as Lilly quits deal
The companies planned to launch a customized version of the YpsoPump that used pre-filled insulin cartridges for Lilly’s rapid-acting insulins.
By Nick Paul Taylor • Dec. 12, 2022 -
Courtesy of Dexcom
Dexcom’s G7 glucose monitor wins awaited FDA clearance
The new Dexcom monitor is expected to generate significant patient demand, as it has been cleared by the FDA for patients with Type 1 and Type 2 diabetes, as well as gestational diabetes.
By Elise Reuter • Dec. 8, 2022 -
Phynart Studio/Getty via Getty Images
AI detects prediabetes in CGM data, opening up new use for device: study
By correctly identifying many patients with prediabetes or Type 2 diabetes, researchers say CGMs can be used to prevent the disease.
By Nick Paul Taylor • Dec. 6, 2022 -
Johnny Greig via Getty Images
The 10 biggest medtech stories of 2022
MedTech Dive reporting this year has explored how companies maintained momentum even amid supply shortages and rising inflation rates.
By MedTech Dive staff • Dec. 3, 2022 -
Permission granted by Embecta
Q&AFriday Q&A: Embecta CEO talks BD spinoff, future of diabetes devices
Dev Kurdikar spoke with MedTech Dive about developing an insulin pump for patients with Type 2 diabetes and what’s next for the firm.
By Elise Reuter • Nov. 18, 2022 -
Courtesy of AEYE Health
AEYE Health wins FDA clearance for AI-powered eye test to expand diabetic screening
Approval is a first step to letting primary care physicians use a hand-held camera backed by AI to diagnose potential diabetic-related sight issues.
By Nick Paul Taylor • Nov. 18, 2022 -
Courtesy of Insulet Corp.
Insulet warns Omnipod 5 insulin pump charge issue may cause fire
Rapid sales growth at the company has come amid safety problems involving some of its devices.
By Nick Paul Taylor • Nov. 17, 2022 -
Courtesy of https://news.medtronic.com/MiniMed-R-670G-Hybrid-Closed-Loop-System#assets_34137_21-122
Medtronic doubles wear time of insulin pump infusion sets
The company calculated users of its extended-wear system will change their devices 75 fewer times, resulting in annual savings of more than $1,000.
By Nick Paul Taylor • Nov. 16, 2022 -
Courtesy of Tandem Diabetes
Tandem pump, paired with Dexcom CGM, boosts blood glucose control in Type 2 diabetics
Patients with Type 2 diabetes spent 3.6 hours per day longer in the target blood glucose range after switching to Tandem’s system, a study found.
By Nick Paul Taylor • Nov. 14, 2022 -
Courtesy of Eli Lilly
Lilly’s new diabetes management platform to integrate Dexcom CGM
The launch comes seven years after the company began investing in device R&D to counter pricing pressures.
By Nick Paul Taylor • Nov. 9, 2022 -
Courtesy of Verily
Verily’s Onduo cut blood sugar in retrospective study of Type 2 diabetics
Participants with high blood sugar at baseline benefited the most from Onduo, a study found.
By Nick Paul Taylor • Nov. 8, 2022
Previous
To find more content, use the "Topics" in the menu above.
